On January 30, 2026, BC Partners and Bpifrance completed the acquisition of Biogaran from Servier, following favorable regulatory approvals and a positive opinion from Biogaran's Social and Economic Committee, with the aim of strengthening the company's position in the French generic medicine market and ensuring its long-term sustainability.

Information on the target

On January 30, 2026, BC Partners, a leading European investor, and Bpifrance announced the successful acquisition of Biogaran from Servier, a key player in the French pharmaceutical industry and one of the leaders in the generic medicine sector in France. This acquisition marks a significant milestone for Biogaran, which is now supported by shareholders committed to its long-term development and its essential role in the sustainability of the French healthcare system.

The completion of this transaction follows the information-consultation procedure of Biogaran's Social and Economic Committee (CSE), which provided a favorable opinion on October 27, 2025. Additionally, all necessary regulatory approvals have been obtained, including the required European authorizations and the approval for foreign investment control from the French government.

Industry overview in the target’s specific country

The French pharmaceutical industry is characterized by its robust regulatory framework and a strong emphasis on innovation and quality. France is one of the largest pharmaceutical markets in Europe, driven by a combination of domestic production and imports.